Guidelines for new obesity drugs must be established
By Moon, sung-ho | translator Kang, Shin-Kook
24.07.26 05:47:42
가나다라
0
Wegovy is expected to enter the Korean market…discussion on how to offer reimbursement for treating patients with extreme obesity is necessary
Obesity is projected to impact around 2 billion individuals by 2035. Including overweight, about 4 billion individuals will be affected by obesity, making it a significant global healthcare issue.
Following this trend, pharmaceutical and biotech industry is focusing on developing next-generation treatments for obesity.
Glucagon-like peptide 1 (GLP-1) drugs, including Saxenda, Wegovy, and Zepbound, showed outstanding weight loss effects in clinical trials. As a result, companies are developing GLP-1-based therapeutics.
▲The number of companies developing obesity drugs by country; big pharmas developing obesity drugs; small businesses and new companies developing obesity drugs.
Recently, these drugs have been found to provide cardiovascular benefits and aid weight loss effects. As a result, their expanded use has been gathe
Moon, sung-ho(lib6983@dailypharm.com)
If you want to see the full article, please JOIN US (click)